Across TCGA pan-cancer cohorts, B3GLCT Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated B3GLCT data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher B3GLCT Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated B3GLCT expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCS, UCEC, and DLBC are the cancer types where B3GLCT Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Median	All	0.007	0.689	<.001	24	view →
UCEC	DFS	Median	All	1.000	0.829	.020	18	view →
DLBC	OS	Median	II,III,IV	0.118	0.802	.025	12	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: B3GLCT tumor-vs-normal RNA expression · all B3GLCT data types